CARING: Digital Health for Caregivers Emotional and Self-management Support

Sponsor
Adhera Health, Inc. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04812665
Collaborator
Hospital Miguel Servet (Other), Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (Industry)
65
1
17.5
3.7

Study Details

Study Description

Brief Summary

This feasibility study builds upon mental health and technology acceptance theoretical frameworks. It seeks to examine potentials of a novel mobile Health (mHealth) solution based on emotional and behavioral change techniques, to provide emotional and self-management tailored support to caregivers of children undergoing Growth Hormone treatment (GHt).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: mHealth solution based on emotional and behavioral change techniques

Detailed Description

This feasibility study builds upon mental health and technology acceptance theoretical frameworks. It seeks to examine potentials of a novel mobile Health (mHealth) solution based on emotional and behavioral change techniques, to provide emotional and self-management tailored support to caregivers of children undergoing Growth Hormone treatment (GHt).

Primary Objectives:
  • To gather qualitative information enabling to better understand individualized experiences of caregiving children undergoing GHt and perceived barriers/facilitators for adoption of the mHealth solution.

  • To assess positive mood states of caregivers of GHt patients as an indicator of emotional wellbeing related to the use of the mHealth solution.

Secondary Objectives:

To explore whether the mHealth solution applied to caregivers of children undergoing GHt might affect:

  • Broader emotion-related parameters: Distress (emotional disturbance), self-efficacy (perceived own capability of managing stress), and general psychological wellbeing of caregivers.

  • Perceived Health-related quality of life (HRQoL) of children (evaluated from the caregivers' perspective).

  • Behavioral parameters: Usability / engagement with the mHealth solution and children's adherence to treatment measured by Easypod-Connect.

Study Design

Study Type:
Observational
Anticipated Enrollment :
65 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Feasibility Study of Digital Health for Caregivers Emotional and Self-management Support of Children Receiving Growth Hormone Treatment
Actual Study Start Date :
May 17, 2021
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Qualitative sub-study (SS1)

One group of caregivers (n = 10) will engage with the mHealth solution during 1 month. Subsequently, an individual semi-structured interview with each of the participants will proceed to gather user experience qualitative information.

Behavioral: mHealth solution based on emotional and behavioral change techniques
Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change. The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs.
Other Names:
  • Adhera
  • Quantitative sub-study (SS2)

    A different group of caregivers (n = 55) will engage with the mHealth solution during 3 months. As elaborated in the following sections, a quantitative approach will be adopted to assess different emotional and behavioral parameters before and after engaging with the mHealth solution (pre-post design).

    Behavioral: mHealth solution based on emotional and behavioral change techniques
    Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change. The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs.
    Other Names:
  • Adhera
  • Outcome Measures

    Primary Outcome Measures

    1. Sub-study 1: Psychological burdens experienced as caregivers of children receiving GHt and barriers/facilitators for adopting the mHealth solution [1 Month]

      A semi-structured interview based on a mental health and technology acceptance theoretical framework has been specifically designed for this purpose

    2. Sub-study 2: Changes on caregiver's positive mood [3 Months]

      Positive subscale of the Positive and Negative Affect Scale (PANAS). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect.

    Secondary Outcome Measures

    1. Emotional outcome: Changes on caregiver's distress [3 Months]

      Distress assessed with the depression, anxiety, and stress scale (DASS-21). DASS-21 is a self-report questionnaire consisting of 21 items, 7 items per subscale: depression, anxiety and stress. Patients are asked to score every item on a scale from 0 (did not apply to me at all) to 3 (applied to me very much). Sum scores are computed by adding up the scores on the items per (sub)scale and multiplying them by a factor 2. Sum scores for the total DASS-total scale thus range between 0 and 120, and those for each of the subscales may range between 0 and 42. Cut-off scores of 60 and 21 are used for the total DASS score and for the subscales respectively. Scores ≥60 (for DASS-total) and ≥21 (for the depression subscale) are labeled as "high" or "severe".

    2. Emotional outcome: Changes on caregiver's general wellbeing [3 Months]

      Assessed with the short form of the Mental Health Continuum - short form questionnaire (MHC-SF). Total sum scores on the MHC-SF can range from 0 to 70, with higher scores indicating higher levels of well-being.

    3. Emotional outcome: Changes on caregiver's perceived self-efficacy [3 Months]

      Perceived self-efficacy assessment with the General Self-Efficacy Scale (GSE), the total score ranges between 10 and 40, with a higher score indicating more self-efficacy.

    4. Health-related Quality of Life (HrQoL): Changes on child's HRQoL [3 Months]

      Children HRQoL assessment with KIDSCREEN-10 index answered by the caregiver as a proxy. The scores ranges between 10 and 50, and are linearly converted into 0-100 scale in which higher scores represent better quality of life.

    5. Health-related Quality of Life (HrQoL): Changes on child's HRQoL [3 Months]

      Child HRQoL assessment with Quality of Life in Short Statured Youth (QoLISSY) questionnaire answered by the caregiver as a proxy. This version has 47 items with a 5-point likert scale each. Total score is linearly transformed into 0 to 100 scores with higher values representing higher HRQOL.

    6. Behavioral outcome: Usability [3 Months]

      mHealth solution usability assessed with the System Usability Scale (SUS) questionnaire. SUS can range between 0 and 100 scores, with higher values representing higher usability.

    7. Behavioral outcome: Treatment adherence [3 Months]

      Adherence to the Growth Hormone treatment (GHt) will be measured with the data collected by the Easypod Connect device.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    The study targets caregivers of GHt patients.

    Inclusion Criteria:
    • Adherence to GHt monitored in the last month prior enrollment indicates a ratio less than 85%.

    • Legal guardian of children who receive GHt in accordance with approved indications in Spain.

    • Explicit agreement on data sharing regarding adherence to GHt gathered through the Easypod Connect.

    • Participants must be able to interact with a smart phone and willing to install the mHealth solution of the study in their smart phone.

    • Participants must sign the specific informed consent form for the study.

    Exclusion Criteria:
    • Candidates without an smart phone or not being able to interact with it.

    • Only one legal guardian per child can participate in the study.

    • Participants of SS1 will not take part in SS2.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Universitario Miguel Servet Zaragoza Aragón Spain 50009

    Sponsors and Collaborators

    • Adhera Health, Inc.
    • Hospital Miguel Servet
    • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

    Investigators

    • Principal Investigator: Luis Fernández-Luque, PhD, Adhera Health, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Adhera Health, Inc.
    ClinicalTrials.gov Identifier:
    NCT04812665
    Other Study ID Numbers:
    • CAR-0220
    First Posted:
    Mar 24, 2021
    Last Update Posted:
    Aug 1, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Adhera Health, Inc.

    Study Results

    No Results Posted as of Aug 1, 2022